Italia markets close in 4 hours 15 minutes

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
160,03+10,32 (+6,89%)
Alla chiusura: 4:00PM EDT

163,67 +3,64 (2,27%)
Preborsa: 7:14AM EDT

Moderna, Inc.

200 Technology Square
Cambridge, MA 02139
United States
617 714 6500
http://www.modernatx.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno1.300

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Noubar B. Afeyan Ph.D.Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board107,5kN/D1963
Mr. Stephane BancelCEO & Director3,86MN/D1973
Dr. Stephen HogePres1,26M19,56M1976
Mr. David W. MelineCFO & Principal Accounting Officer932,62kN/D1957
Dr. Tal ZaksChief Medical Officer1,25M67,49M1966
Mr. Juan AndresChief Technical Operations & Quality Officer1,25M9,32M1965
Dr. John V. W. ReyndersChief Information OfficerN/DN/DN/D
Dr. Melissa J. MooreChief Scientific Officer & Member of Scientific Advisory BoardN/DN/DN/D
Ms. Lavina Talukdar CFASr. VP & Head of Investor RelationsN/DN/DN/D
Ms. Lori M. Henderson J.D., Esq.Gen. Counsel & Corp. Sec.N/DN/D1962
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., and Recipharm for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Moderna, Inc. al 1 aprile 2021 è 7. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.